schliessen

Filtern

 

Bibliotheken

Evaluation of [sup.188]Re-labeled PEGylated nanoliposome as a radionuclide therapeutic agent in an orthotopic glioma-bearing rat model.(ORIGINAL RESEARCH)(Report)

Purpose: In this study, the [sup.188]Re-labeled PEGylated nanoliposome ([sup.188]Re-liposome) was prepared and evaluated as a therapeutic agent for glioma. Materials and methods: The reporter cell line, [F98.sub.luc] was prepared via Lentivector expression kit system and used to set up the orthotopi... Full description

Journal Title: International Journal of Nanomedicine 2015, Vol.10, p.463(11)
Main Author: Huang, Feng-Yun J.
Other Authors: Lee, Te-Wei , Chang, Chih-Hsien , Chen, Liang-Cheng , Hsu, Wei-Hsin , Chang, Chien-Wen , Lo, Jem-Mau
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 1178-2013 ; DOI: 10.2147/IJN.S75955
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: gale_ofa446734878
title: Evaluation of [sup.188]Re-labeled PEGylated nanoliposome as a radionuclide therapeutic agent in an orthotopic glioma-bearing rat model.(ORIGINAL RESEARCH)(Report)
format: Article
creator:
  • Huang, Feng-Yun J.
  • Lee, Te-Wei
  • Chang, Chih-Hsien
  • Chen, Liang-Cheng
  • Hsu, Wei-Hsin
  • Chang, Chien-Wen
  • Lo, Jem-Mau
subjects:
  • Liposomes – Usage
  • Liposomes – Properties
  • Liposomes – Research
  • Antineoplastic Agents – Dosage and Administration
  • Antineoplastic Agents – Complications and Side Effects
  • Gliomas – Drug Therapy
  • Gliomas – Research
ispartof: International Journal of Nanomedicine, 2015, Vol.10, p.463(11)
description: Purpose: In this study, the [sup.188]Re-labeled PEGylated nanoliposome ([sup.188]Re-liposome) was prepared and evaluated as a therapeutic agent for glioma. Materials and methods: The reporter cell line, [F98.sub.luc] was prepared via Lentivector expression kit system and used to set up the orthotopic glioma-bearing rat model for non-invasive bioluminescent imaging. The maximum tolerated dose applicable in Fischer344 rats was explored via body weight monitoring of the rats after single intravenous injection of [sup.188]Re-liposome with varying dosages before the treatment study. The OLINDA/EXM 1.1 software was utilized for estimating the radiation dosimetry. To assess the therapeutic efficacy, tumor-bearing rats were intravenously administered [sup.188]Re-liposome or normal saline followed by monitoring of the tumor growth and animal survival time. In addition, the histopathological examinations of tumors were conducted on the [sup.188]Re-liposome-treated rats. Results: By using bioluminescent imaging, the well-established reporter cell line ([F98.sub.luc]) showed a high relationship between cell number and its bioluminescent intensity ([R.sup.2]=0.99) in vitro; furthermore, it could also provide clear tumor imaging for monitoring tumor growth in vivo. The maximum tolerated dose of [sup.188]Re-liposome in Fischer344 rats was estimated to be 333 MBq. According to the dosimetry results, higher equivalent doses were observed in spleen and kidneys while very less were in normal brain, red marrow, and thyroid. For therapeutic efficacy study, the progression of tumor growth in terms of tumor volume and/or tumor weight was significantly slower for the [sup.188]Re-liposome-treated group than the control group (P
language: eng
source:
identifier: ISSN: 1178-2013 ; DOI: 10.2147/IJN.S75955
fulltext: fulltext
issn:
  • 1178-2013
  • 11782013
url: Link


@attributes
ID1172954311
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid446734878
sourceidgale_ofa
recordidTN_gale_ofa446734878
sourceformatXML
sourcesystemPC
pqid2238127681
galeid446734878
display
typearticle
titleEvaluation of [sup.188]Re-labeled PEGylated nanoliposome as a radionuclide therapeutic agent in an orthotopic glioma-bearing rat model.(ORIGINAL RESEARCH)(Report)
creatorHuang, Feng-Yun J. ; Lee, Te-Wei ; Chang, Chih-Hsien ; Chen, Liang-Cheng ; Hsu, Wei-Hsin ; Chang, Chien-Wen ; Lo, Jem-Mau
ispartofInternational Journal of Nanomedicine, 2015, Vol.10, p.463(11)
identifierISSN: 1178-2013 ; DOI: 10.2147/IJN.S75955
subjectLiposomes – Usage ; Liposomes – Properties ; Liposomes – Research ; Antineoplastic Agents – Dosage and Administration ; Antineoplastic Agents – Complications and Side Effects ; Gliomas – Drug Therapy ; Gliomas – Research
descriptionPurpose: In this study, the [sup.188]Re-labeled PEGylated nanoliposome ([sup.188]Re-liposome) was prepared and evaluated as a therapeutic agent for glioma. Materials and methods: The reporter cell line, [F98.sub.luc] was prepared via Lentivector expression kit system and used to set up the orthotopic glioma-bearing rat model for non-invasive bioluminescent imaging. The maximum tolerated dose applicable in Fischer344 rats was explored via body weight monitoring of the rats after single intravenous injection of [sup.188]Re-liposome with varying dosages before the treatment study. The OLINDA/EXM 1.1 software was utilized for estimating the radiation dosimetry. To assess the therapeutic efficacy, tumor-bearing rats were intravenously administered [sup.188]Re-liposome or normal saline followed by monitoring of the tumor growth and animal survival time. In addition, the histopathological examinations of tumors were conducted on the [sup.188]Re-liposome-treated rats. Results: By using bioluminescent imaging, the well-established reporter cell line ([F98.sub.luc]) showed a high relationship between cell number and its bioluminescent intensity ([R.sup.2]=0.99) in vitro; furthermore, it could also provide clear tumor imaging for monitoring tumor growth in vivo. The maximum tolerated dose of [sup.188]Re-liposome in Fischer344 rats was estimated to be 333 MBq. According to the dosimetry results, higher equivalent doses were observed in spleen and kidneys while very less were in normal brain, red marrow, and thyroid. For therapeutic efficacy study, the progression of tumor growth in terms of tumor volume and/or tumor weight was significantly slower for the [sup.188]Re-liposome-treated group than the control group (P<0.05). As a result, the lifespan of glioma-bearing rats treated with [sup.188]Re-liposome was prolonged 10.67% compared to the control group. Conclusion: The radiotherapeutic evaluation by dosimetry and survival studies have demonstrated that passive targeting [sup.188]Re-liposome via systemic administration can significantly prolong the lifespan of orthotopic glioma-bearing rats while maintaining reasonable systemic radiation safety. Therefore, [sup.188]Re-liposome could be a potential therapeutic agent for glioblastoma multiforme treatment. Keywords: [sup.188]Re, liposome, radionuclide therapy, bioluminescent imaging, glioma
languageeng
source
version11
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
search
scope
0gale_onefilea
1OneFile
creatorcontrib
0Huang, Feng-Yun J
1Lee, Te-Wei
2Chang, Chih-Hsien
3Chen, Liang-Cheng
4Hsu, Wei-Hsin
5Chang, Chien-Wen
6Lo, Jem-Mau
titleEvaluation of [sup.188]Re-labeled PEGylated nanoliposome as a radionuclide therapeutic agent in an orthotopic glioma-bearing rat model.(ORIGINAL RESEARCH)(Report)
descriptionPurpose: In this study, the [sup.188]Re-labeled PEGylated nanoliposome ([sup.188]Re-liposome) was prepared and evaluated as a therapeutic agent for glioma. Materials and methods: The reporter cell line, [F98.sub.luc] was prepared via Lentivector expression kit system and used to set up the orthotopic glioma-bearing rat model for non-invasive bioluminescent imaging. The maximum tolerated dose applicable in Fischer344 rats was explored via body weight monitoring of the rats after single intravenous injection of [sup.188]Re-liposome with varying dosages before the treatment study. The OLINDA/EXM 1.1 software was utilized for estimating the radiation dosimetry. To assess the therapeutic efficacy, tumor-bearing rats were intravenously administered [sup.188]Re-liposome or normal saline followed by monitoring of the tumor growth and animal survival time. In addition, the histopathological examinations of tumors were conducted on the [sup.188]Re-liposome-treated rats. Results: By using bioluminescent imaging, the well-established reporter cell line ([F98.sub.luc]) showed a high relationship between cell number and its bioluminescent intensity ([R.sup.2]=0.99) in vitro; furthermore, it could also provide clear tumor imaging for monitoring tumor growth in vivo. The maximum tolerated dose of [sup.188]Re-liposome in Fischer344 rats was estimated to be 333 MBq. According to the dosimetry results, higher equivalent doses were observed in spleen and kidneys while very less were in normal brain, red marrow, and thyroid. For therapeutic efficacy study, the progression of tumor growth in terms of tumor volume and/or tumor weight was significantly slower for the [sup.188]Re-liposome-treated group than the control group (P<0.05). As a result, the lifespan of glioma-bearing rats treated with [sup.188]Re-liposome was prolonged 10.67% compared to the control group. Conclusion: The radiotherapeutic evaluation by dosimetry and survival studies have demonstrated that passive targeting [sup.188]Re-liposome via systemic administration can significantly prolong the lifespan of orthotopic glioma-bearing rats while maintaining reasonable systemic radiation safety. Therefore, [sup.188]Re-liposome could be a potential therapeutic agent for glioblastoma multiforme treatment. Keywords: [sup.188]Re, liposome, radionuclide therapy, bioluminescent imaging, glioma
subject
0Liposomes–Usage
1Liposomes–Properties
2Liposomes–Research
3Antineoplastic agents–Dosage and administration
4Antineoplastic agents–Complications and side effects
5Gliomas–Drug therapy
6Gliomas–Research
72834
8Pharmaceutical preparations
9Biological Product (except Diagnostic) Manufacturing
10Pharmaceutical Preparation Manufacturing
11325414
12325412
13Taiwan
149TAIW
general
010.2147/IJN.S75955
1English
2Dove Medical Press Limited
3Cengage Learning, Inc.
sourceidgale_ofa
recordidgale_ofa446734878
issn
01178-2013
111782013
rsrctypearticle
creationdate2015
startdate20150101
enddate20150101
recordtypearticle
addtitleInternational Journal of Nanomedicine
searchscopeOneFile
citationpf 463 vol 10
lsr30VSR-Enriched:[pages, galeid, pqid, issue]
sort
titleEvaluation of [sup.188]Re-labeled PEGylated nanoliposome as a radionuclide therapeutic agent in an orthotopic glioma-bearing rat model.(ORIGINAL RESEARCH)(Report)
authorHuang, Feng-Yun J. ; Lee, Te-Wei ; Chang, Chih-Hsien ; Chen, Liang-Cheng ; Hsu, Wei-Hsin ; Chang, Chien-Wen ; Lo, Jem-Mau
creationdate20150101
lso0120150101
facets
frbrgroupid-421377963143770926
frbrtype5
languageeng
creationdate2015
topic
0Liposomes–Usage
1Liposomes–Properties
2Liposomes–Research
3Antineoplastic Agents–Dosage and Administration
4Antineoplastic Agents–Complications and Side Effects
5Gliomas–Drug Therapy
6Gliomas–Research
collectionOneFile (GALE)
prefilterarticles
rsrctypearticles
creatorcontrib
0Huang, Feng-Yun J.
1Lee, Te-Wei
2Chang, Chih-Hsien
3Chen, Liang-Cheng
4Hsu, Wei-Hsin
5Chang, Chien-Wen
6Lo, Jem-Mau
jtitleInternational Journal of Nanomedicine
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Huang
1Lee
2Chang
3Chen
4Hsu
5Lo
aufirst
0Feng-Yun J.
1Te-Wei
2Chih-Hsien
3Liang-Cheng
4Wei-Hsin
5Chien-Wen
6Jem-Mau
au
0Huang, Feng-Yun J.
1Lee, Te-Wei
2Chang, Chih-Hsien
3Chen, Liang-Cheng
4Hsu, Wei-Hsin
5Chang, Chien-Wen
6Lo, Jem-Mau
atitleEvaluation of [sup.188]Re-labeled PEGylated nanoliposome as a radionuclide therapeutic agent in an orthotopic glioma-bearing rat model.
risdate20150101
volume10
spage463
issn1178-2013
formatjournal
genrearticle
ristypeJOUR
abstractPurpose: In this study, the [sup.188]Re-labeled PEGylated nanoliposome ([sup.188]Re-liposome) was prepared and evaluated as a therapeutic agent for glioma. Materials and methods: The reporter cell line, [F98.sub.luc] was prepared via Lentivector expression kit system and used to set up the orthotopic glioma-bearing rat model for non-invasive bioluminescent imaging. The maximum tolerated dose applicable in Fischer344 rats was explored via body weight monitoring of the rats after single intravenous injection of [sup.188]Re-liposome with varying dosages before the treatment study. The OLINDA/EXM 1.1 software was utilized for estimating the radiation dosimetry. To assess the therapeutic efficacy, tumor-bearing rats were intravenously administered [sup.188]Re-liposome or normal saline followed by monitoring of the tumor growth and animal survival time. In addition, the histopathological examinations of tumors were conducted on the [sup.188]Re-liposome-treated rats. Results: By using bioluminescent imaging, the well-established reporter cell line ([F98.sub.luc]) showed a high relationship between cell number and its bioluminescent intensity ([R.sup.2]=0.99) in vitro; furthermore, it could also provide clear tumor imaging for monitoring tumor growth in vivo. The maximum tolerated dose of [sup.188]Re-liposome in Fischer344 rats was estimated to be 333 MBq. According to the dosimetry results, higher equivalent doses were observed in spleen and kidneys while very less were in normal brain, red marrow, and thyroid. For therapeutic efficacy study, the progression of tumor growth in terms of tumor volume and/or tumor weight was significantly slower for the [sup.188]Re-liposome-treated group than the control group (P<0.05). As a result, the lifespan of glioma-bearing rats treated with [sup.188]Re-liposome was prolonged 10.67% compared to the control group. Conclusion: The radiotherapeutic evaluation by dosimetry and survival studies have demonstrated that passive targeting [sup.188]Re-liposome via systemic administration can significantly prolong the lifespan of orthotopic glioma-bearing rats while maintaining reasonable systemic radiation safety. Therefore, [sup.188]Re-liposome could be a potential therapeutic agent for glioblastoma multiforme treatment. Keywords: [sup.188]Re, liposome, radionuclide therapy, bioluminescent imaging, glioma
pubDove Medical Press Limited
doi10.2147/IJN.S75955
lad01gale_ofa
pages463-46373
issue1
date2015-01-01